Posted by Michael Wonder on 29 Jan 2026
QTX-2101 awarded FDA fast track designation for the treatment of acute promyelocytic leukaemia
29 January 2026 - Quetzal Therapeutics announced that the US FDA has granted fast track designation to QTX-2101, the company’s investigational oral arsenic trioxide capsule, for the treatment of patients with acute promyelocytic leukaemia.
QTX-2101 is an oral capsule formulation of arsenic trioxide developed with the goal of addressing limitations associated with intravenous administration, including the need for frequent clinic visits.
